Evidence map›Paper›PMID 40716110›Full record

ArticleProtein science : a publication of the Protein Society2025

Deep sequencing combined with high-throughput screening enables efficient development of a pH-dependent high-affinity binding domain targeting HER3.

Marit Möller, Malin Jönsson, Magnus Lundqvist, Johan Rockberg, John Löfblom, Hanna Tegel, Sophia Hober

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marit MöllerDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
Malin JönssonDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
Magnus LundqvistDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
Johan RockbergDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
John LöfblomDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.
Hanna TegelDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0002-7067-9173
Sophia HoberDepartment of Protein Science, KTH-Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0003-0605-8417

Funding

Cancerfonden 22 2144 PjVetenskapsrådet 2021-04289_VR
6 · The paper itself

Abstract

In vitro methods for developing binding domains have been well-established for many years, owing to the cost-efficient synthesis of DNA and high-throughput selection and screening technologies. However, generating high-affinity binding domains often requires the development of focused maturation libraries for a second selection, which typically demands a detailed understanding of the binding surfaces from the initial selection, a process that can be time-consuming. In this study, we accelerated this process by using deep sequencing data from the first selection to guide the design of the maturation library. Additionally, we employed a high-throughput screening system using flow cytometry based on Escherichia coli display to identify conditional binding domains from the selection output. This approach enabled the development of a high-affinity binder targeting the cancer biomarker HER3, with a binding affinity of 3.3 nM at extracellular pH 7.4, 100 times higher than the first-generation binding domain. Notably, the binding domain features a pH-dependent release mechanism, enabling rapid release in slightly acidic environments (pH ≈6), which resemble endosomal conditions. When conjugated to the cytotoxin mertansine (DM1), the binding domain demonstrated specific cytotoxic activity against HER3-expressing cell lines, with an IC50 of 2-5 nM. The presented approach enables the efficient development of conditional binding domains which hold promise for therapeutic applications.

Indexed as

High-Throughput Nucleotide SequencingHigh-Throughput Screening AssaysReceptor, ErbB-3Escherichia coliHumansHydrogen-Ion ConcentrationProtein BindingProtein DomainsERBB3 protein, humanReceptor, ErbB-3calcium‐regulated affinitycancercell display screeningconditional targetingdeep sequencingdrug conjugateendosomal releaseHER3

Identifiers

PMID40716110
PMCPMC12679944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.